Therefore, combination therapy with olaparib plus paclitaxel can be used as a second-line treatment for patients with advanced-stage/recurrent GC who had HRD and/or BRCA1/2 mutations with PVs. This evidence concerns the gene BRCA1 and gastric cancer.